: Updated recommendations for first-line maintenance using PARP inhibitors like rucaparib and the introduction of antibody-drug conjugates (ADCs) like MIRV for recurrent cases.
: Inclusion of newly approved regimens, such as pembrolizumab in combination with paclitaxel for platinum-resistant cases.
Medical publications and guides such as those from ESMO and Oncologik often include the following technical features: